In vitro study of anticancer acridines as potential antitrypanosomal and antimalarial agents.
The requirement for rational drug design in the search for new agents that are active against parasitic protozoa prompted our in vitro studies with a group of 9-anilinoacridines. In vitro growth assays with Trypanosoma lewisi identified a series of C-1' alkylaminoacridines which possess previously unreported potent growth-inhibitory activities against T. lewisi at a concentration range of 0.1 to 1 microM. In contrast, several 9-anilinoacridines that possess acridine ring NH2 substituents at C-3 and C-6 were inactive against T. lewisi, but they possessed strong activity against Plasmodium falciparum at a concentration range of 0.1 to 2.8 microM. In mammalian cells, amsacrine [4'-(9-acridinylamino)methanesulfon-m-anisidide] inhibits DNA topoisomerase II; however, amsacrine was only weakly active against T. lewisi. Such differences in the patterns of susceptibility of mammalian cells, T. lewisi, and P. falciparum to these 9-anilinoacridines may reflect enzyme differences between different parasites and mammalian cells that can be exploited by further improvements in drug design.
Figgitt
D
D
Department of Cellular Biology, University of Auckland, New Zealand.
Denny
W
W
Chavalitshewinkoon
P
P
Wilairat
P
P
Ralph
R
R
D000166:Acridines / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000962:Antimalarials / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002478:Cells, Cultured; D006801:Humans; D009115:Muridae; D010963:Plasmodium falciparum / Q000187:drug effects*; D013329:Structure-Activity Relationship; D014344:Trypanocidal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D014350:Trypanosoma lewisi / Q000187:drug effects*; D014352:Trypanosomiasis / Q000188:drug therapy / Q000469:parasitology
D000166:Acridines; D000962:Antimalarials; D000970:Antineoplastic Agents; D014344:Trypanocidal Agents